BAY 2253651
Alternative Names: BAY2253651Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Bayer
- Class Sleep disorder therapies
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sleep apnoea syndrome
Most Recent Events
- 09 Mar 2021 Discontinued - Phase-II for Sleep apnoea syndrome in Switzerland, United Kingdom (Intranasal) as BAY 2253651 failed to demonstrate sufficient efficacy
- 02 Sep 2019 Bayer completes the phase II SANDMAN trial in Sleep apnoea in United Kingdom and Switzerland (NCT03603678)
- 13 Aug 2018 Phase-II clinical trials in Sleep apnoea syndrome in Switzerland, United Kingdom (Intranasal) (NCT03603678) (EudraCT2017-001851-29)